FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059911857> ?p ?o ?g. }

• W2059911857 endingPage "5500" @default.
• W2059911857 startingPage "5500" @default.
• W2059911857 abstract "Abstract The poly ADP-ribose polymerase (PARP) inhibitors are novel agents being developed with the hope of inhibiting base excision repair, a process that is of prime importance for tumors to survive genotoxic insult. BRCA gene homozygous deficiency has been identified as a potential predictor of response to PARP inhibitors. BRCA is involved in homologous recombination (HR), an example of double-strand break repair. Thus, inhibiting tumors which have lost one DNA repair pathway by targeting a second DNA repair pathway represents groundbreaking therapeutic strategy. BRCA is just one of many genes that collaborate in the same repair pathway, which has been named the Fanconi Anemia (FA) pathway. The FA pathway is a major mechanism of homologous recombination DNA repair in response to genotoxic insults. Deficiencies in FA pathway have been reported as a predictor of cisplatin and mitomycin C (MMC) sensitivity in cancer cells. Given that this pathway plays essential roles in response to the DNA damage, cancers with defective FA pathway are expected to be more sensitive to DNA cross-link based therapy, or to treatments in which additional repair mechanisms are targeted. In order to preclinically evaluate the effect of PARP inhibition in lung cancer cells with spontaneously defective FA pathway, we utilized RNAi technology to create FANCD2 knockdown cancer cells. Lung cancer cells H1299 and A549 were transduced with FANCD2-specific shRNA-expressing and puromycin-resistant lentiviral particles, or control shRNA lentiviral particles to create stably transduced cells. Successful FANCD2 knockdown was confirmed by the Western blot by reduction in the FANCD2 protein. Cell viability was evaluated with MTT (Dimethylthiazolyl-2-5-diphenyltetrazolium bromide) analysis. The FA defective H1299 and A549 lung cancer cells and the controls (transected with empty vectors) were treated with the PARP inhibitor ABT888 at a dose of 5µM. Then the treated cells were harvested at 24, 48 and 72 hours post treatment. MTT cell viability analysis showed that ABT888 alone was cytotoxic to the FA deficient lung cancer cells (H1299D2-down and A549D2-down) 72 hours post treatment. In both cell types, the FA defective lung cancer cells had less viable cells compared to controls 72 hours post treatment. Recent clinical data confirmed the PARP inhibitors could be used not only as chemosensitizers but as well as single agents to selective kill tumors with BRCA-deficient breast cancers. Disruption of FA cascade has been reported in solid tumors. Given that the FA pathway plays an essential role in response to therapy-induced DNA interstrand cross-links, it is very plausible that cancers with defective FA pathway are more sensitive to cross-link based therapy and that treatments like PARP inhibitors in which an additional repair mechanism is targeted. A clinical trial to validate this hypothesis is under way. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5500. doi:10.1158/1538-7445.AM2011-5500" @default.
• W2059911857 created "2016-06-24" @default.
• W2059911857 creator A5004712121 @default.
• W2059911857 creator A5015548619 @default.
• W2059911857 creator A5039441880 @default.
• W2059911857 creator A5060693402 @default.
• W2059911857 creator A5088264063 @default.
• W2059911857 date "2011-04-01" @default.
• W2059911857 modified "2023-10-13" @default.
• W2059911857 title "Abstract 5500: Inhibition of poly(ADP-ribose) polymerase in lung cancer cells with defective Fanconi anemia (FA) pathway" @default.
• W2059911857 doi "https://doi.org/10.1158/1538-7445.am2011-5500" @default.
• W2059911857 hasPublicationYear "2011" @default.
• W2059911857 type Work @default.
• W2059911857 sameAs 2059911857 @default.
• W2059911857 citedByCount "4" @default.
• W2059911857 countsByYear W20599118572013 @default.
• W2059911857 countsByYear W20599118572020 @default.
• W2059911857 crossrefType "journal-article" @default.
• W2059911857 hasAuthorship W2059911857A5004712121 @default.
• W2059911857 hasAuthorship W2059911857A5015548619 @default.
• W2059911857 hasAuthorship W2059911857A5039441880 @default.
• W2059911857 hasAuthorship W2059911857A5060693402 @default.
• W2059911857 hasAuthorship W2059911857A5088264063 @default.
• W2059911857 hasConcept C102744134 @default.
• W2059911857 hasConcept C121608353 @default.
• W2059911857 hasConcept C134935766 @default.
• W2059911857 hasConcept C143425029 @default.
• W2059911857 hasConcept C153911025 @default.
• W2059911857 hasConcept C173396325 @default.
• W2059911857 hasConcept C182979987 @default.
• W2059911857 hasConcept C187206112 @default.
• W2059911857 hasConcept C190232843 @default.
• W2059911857 hasConcept C2776653068 @default.
• W2059911857 hasConcept C2776694085 @default.
• W2059911857 hasConcept C2778124228 @default.
• W2059911857 hasConcept C2778239845 @default.
• W2059911857 hasConcept C502942594 @default.
• W2059911857 hasConcept C54355233 @default.
• W2059911857 hasConcept C552990157 @default.
• W2059911857 hasConcept C81885089 @default.
• W2059911857 hasConcept C82381507 @default.
• W2059911857 hasConcept C86803240 @default.
• W2059911857 hasConceptScore W2059911857C102744134 @default.
• W2059911857 hasConceptScore W2059911857C121608353 @default.
• W2059911857 hasConceptScore W2059911857C134935766 @default.
• W2059911857 hasConceptScore W2059911857C143425029 @default.
• W2059911857 hasConceptScore W2059911857C153911025 @default.
• W2059911857 hasConceptScore W2059911857C173396325 @default.
• W2059911857 hasConceptScore W2059911857C182979987 @default.
• W2059911857 hasConceptScore W2059911857C187206112 @default.
• W2059911857 hasConceptScore W2059911857C190232843 @default.
• W2059911857 hasConceptScore W2059911857C2776653068 @default.
• W2059911857 hasConceptScore W2059911857C2776694085 @default.
• W2059911857 hasConceptScore W2059911857C2778124228 @default.
• W2059911857 hasConceptScore W2059911857C2778239845 @default.
• W2059911857 hasConceptScore W2059911857C502942594 @default.
• W2059911857 hasConceptScore W2059911857C54355233 @default.
• W2059911857 hasConceptScore W2059911857C552990157 @default.
• W2059911857 hasConceptScore W2059911857C81885089 @default.
• W2059911857 hasConceptScore W2059911857C82381507 @default.
• W2059911857 hasConceptScore W2059911857C86803240 @default.
• W2059911857 hasIssue "8_Supplement" @default.
• W2059911857 hasLocation W20599118571 @default.
• W2059911857 hasOpenAccess W2059911857 @default.
• W2059911857 hasPrimaryLocation W20599118571 @default.
• W2059911857 hasRelatedWork W1653285373 @default.
• W2059911857 hasRelatedWork W2035667749 @default.
• W2059911857 hasRelatedWork W2053054375 @default.
• W2059911857 hasRelatedWork W2090726258 @default.
• W2059911857 hasRelatedWork W2107254805 @default.
• W2059911857 hasRelatedWork W2125047184 @default.
• W2059911857 hasRelatedWork W2153025234 @default.
• W2059911857 hasRelatedWork W2607159183 @default.
• W2059911857 hasRelatedWork W3040316671 @default.
• W2059911857 hasRelatedWork W3216431082 @default.
• W2059911857 hasVolume "71" @default.
• W2059911857 isParatext "false" @default.
• W2059911857 isRetracted "false" @default.
• W2059911857 magId "2059911857" @default.
• W2059911857 workType "article" @default.